2 days ago
LEO Pharma Adds Skin Drug from Boehringer as It Readies for IPO
LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the Danish dermatology specialist strengthens its portfolio ahead of a planned initial public offering in 2026.
Under the deal, LEO Pharma will take over global commercialization and further development of the drug, which treats generalized pustular psoriasis, or GPP, a rare and potentially life-threatening condition, LEO said in press release on Monday. Boehringer will receive an upfront payment of €90 million ($110 million) and is eligible for future milestone and royalty payments.
